Status:
COMPLETED
Remimazolam Total Intravenous Anesthesia Under Analgesia Nociception Index-guidance
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Knee Osteoarthritis
Total Knee Arthroplasty
Eligibility:
All Genders
19-80 years
Phase:
NA
Brief Summary
The investigators hypothesized that intraoperative opioid consumption would be different between remimazolam and propofol if the ANI-guided remifentanil continuous infusion rate was adjusted when the ...
Eligibility Criteria
Inclusion
- Patients 19\~80 years of age who are expected to elective total knee arthroplasty under general anesthesia
- ASA PS 1-3
Exclusion
- Second total knee arthroplasty under a prior plan of staged total knee arthroplasty, both
- Previous hepatectomy or liver transplant
- Estimated glomerular filtration rate \< 30 mL/min/1.73m2
- Patients with moderate or more hepatic impairment (AST/ALT is more than 2.5 times the upper limit of normal)
- Uncontrolled hypertension (systolic blood pressure \> 160mmHg)
- Acute narrow angle glaucoma
- Myasthesia gravis
- Known allergy to the drugs included in the study
- Cardiac arrhthmia (non-sinus rhythm)
- Taking drugs that affect the autonomic nervous system of diabetes
- Psychiatric or neurologic disease (major depression disorder, dementia or cerebral infarction)
- History of drug or alcohol abuse
Key Trial Info
Start Date :
June 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 18 2023
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT05322902
Start Date
June 2 2022
End Date
July 18 2023
Last Update
July 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gangnam Severance Hospital
Seoul, South Korea